关于利妥昔治疗恶性淋巴瘤的研究进展

关于利妥昔治疗恶性淋巴瘤的研究进展(论文7500字)
摘要：利妥昔是针对B淋巴细胞表面 CD20抗原的单克隆抗体，具有较强的抗肿瘤活性，目前已广泛应用于恶性淋巴瘤的治疗，大量研究结果表明利妥昔对于治疗大部分成熟 B细胞型非霍奇金淋巴瘤的效果显著。本文总结了近年来关于利妥昔治疗恶性淋巴瘤的的相关文献，对其的研究进展进行了总结。
关键词：利妥昔；恶性淋巴瘤；B细胞

Progress in rituximab in the treatment of malignant lymphoma
(Medicine and Nursing Department of Dezhou University, Dezhou Shandong, 253023)
Abstract:As a monoclonal antibody against the surface CD20 antigen of B lymphocytes, it has a strong antitumor activity and has been widely used in the treatment of malignant lymphoma, and a large number of studies have shown that the effect of topiramate is significant for the treatment of most mature B-cell non-Hodgkin's lymphoma. In this paper, the related literatures about the treatment of the patients with malignant lymphoma in recent years are summarized, and the research progress is summarized.
Key Words：Rituximab,Malignant Lymphoma,Bcell

目录
摘要及关键词    1
前言    1
1 临床应用    2
1.1 弥漫大B细胞淋巴瘤    2
1.2 滤泡性非霍奇金淋巴瘤    3
1.3 套细胞淋巴瘤    4
1.4 伯基特淋巴瘤    4
1.5 黏膜相关淋巴样组织结节外边缘区淋巴瘤    5
1.6 血管免疫母细胞性T细胞淋巴瘤    5
1.7 霍奇金淋巴瘤    5
1.8 小淋巴细胞淋巴瘤    6
2 利妥昔治疗恶性淋巴瘤的不良反应    6
2.1 感染    6
2.2 血液疾病    6
3 利妥昔的耐药问题    7
4 问题与展望    7
参考文献    7
谢 辞    10